Cargando…
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
The anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with B-cell malignancies were examined in a real-world setting. A next-generation sequencing (NGS)–based molecular assay was used to assess SARS-CoV-2–specific T-cell responses. After the second dose, 58% (166/284)...
Autores principales: | Greenberger, Lee M., Saltzman, Larry A., Gruenbaum, Lore M., Xu, Jun, Reddy, Sneha T., Senefeld, Jonathon W., Johnson, Patrick W., Fields, Paul A., Sanders, Catherine, DeGennaro, Louis J., Nichols, Gwen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894565/ https://www.ncbi.nlm.nih.gov/pubmed/36074641 http://dx.doi.org/10.1158/2643-3230.BCD-22-0077 |
Ejemplares similares
-
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021) -
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021) -
Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies during the Omicron (B.1.1.529) Surge: Data from the Patient-Reported Leukemia & Lymphoma Society National Registry
por: Reddy, Sneha T, et al.
Publicado: (2022) -
Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021) -
Danger ahead: COVID-19 infections after vaccination
por: Greenberger, Lee M., et al.
Publicado: (2022)